NANOMOL TECHNOLOGIES SL

Their core work

Nanomol Technologies is a Spanish SME specializing in the design and manufacture of nanoparticle-based drug delivery systems, with particular strength in liposomal and lipid-based nanocarriers. They develop scalable manufacturing processes (including GMP-compliant production) for nanopharmaceuticals that can cross biological barriers such as the blood-brain barrier and cellular membranes. Their work spans from formulation design through to pilot-scale production, serving the pharmaceutical and biomedical sectors with enabling nanotechnology platforms.

What they specialise in

How they've shifted over time

In their early H2020 period (2017–2020), Nanomol Technologies focused heavily on therapeutic nanocarrier development — liposomal formulations for rare diseases like Fabry, DNA-based oligonucleotide platforms, and overcoming biological barriers (BBB crossing, membrane penetration). Their more recent projects (2021 onwards) show a shift toward manufacturing infrastructure and diagnostic/imaging applications, with Phoenix providing a pilot-scale test bed for nanopharmaceuticals and Micro4Nano moving into fluorescence-based bioimaging and microfluidic production methods. The trajectory suggests a company maturing from formulation R&D toward scalable production services and broadening its application base beyond therapeutics.

Nanomol is evolving from a pure drug-delivery formulator into a nanopharmaceutical manufacturing and characterization service provider, making them increasingly relevant as a production partner for pharma and biotech companies.

How they like to work

Nanomol Technologies consistently participates as a partner rather than a coordinator, indicating they contribute specialized nanoformulation and manufacturing expertise to larger consortia rather than leading project design. With 40 unique partners across 19 countries from just 4 projects, they operate in broad, international consortia — typical of MSCA-RISE and large Innovation Actions. This makes them an accessible, experienced consortium partner who integrates well into multi-country teams without demanding a leadership seat.

Despite only 4 projects, Nanomol has built a remarkably wide network of 40 partners across 19 countries, reflecting the large consortia typical of MSCA-RISE mobility projects and Innovation Actions. Their reach is genuinely pan-European with likely connections extending to associated countries.

What sets them apart

Nanomol Technologies occupies a rare niche as an SME that bridges nanoparticle formulation science and GMP-compliant manufacturing — most companies do one or the other. Based near Barcelona (Cerdanyola del Vallès, home to the UAB research campus), they sit at the interface between academic nanotechnology research and industrial pharmaceutical production. For consortium builders, they offer a credible industry partner that can take lab-scale nanoformulations and move them toward manufacturing readiness, which is exactly the kind of technology transfer capability that EU reviewers value.

Highlights from their portfolio

• Phoenix
  Largest project by funding (€904K to Nanomol), an open innovation test bed for nanopharmaceutical manufacturing — positions them as a production-scale service provider.
• Smart-4-Fabry
  Most technically specific project: GMP-compliant nanocarrier production for a rare disease (Fabry), demonstrating real therapeutic application with manufacturing focus.
• Micro4Nano
  Signals a new direction into bioimaging tools and microfluidic production, diversifying beyond drug delivery into diagnostics and research instrumentation.